JP2025505745A5 - - Google Patents

Info

Publication number
JP2025505745A5
JP2025505745A5 JP2024547667A JP2024547667A JP2025505745A5 JP 2025505745 A5 JP2025505745 A5 JP 2025505745A5 JP 2024547667 A JP2024547667 A JP 2024547667A JP 2024547667 A JP2024547667 A JP 2024547667A JP 2025505745 A5 JP2025505745 A5 JP 2025505745A5
Authority
JP
Japan
Application number
JP2024547667A
Other languages
Japanese (ja)
Other versions
JPWO2023156453A5 (https=
JP2025505745A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/053752 external-priority patent/WO2023156453A1/en
Publication of JP2025505745A publication Critical patent/JP2025505745A/ja
Publication of JP2025505745A5 publication Critical patent/JP2025505745A5/ja
Publication of JPWO2023156453A5 publication Critical patent/JPWO2023156453A5/ja
Pending legal-status Critical Current

Links

JP2024547667A 2022-02-15 2023-02-15 フェネチルアミン誘導体、組成物、及び使用方法 Pending JP2025505745A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263268024P 2022-02-15 2022-02-15
US202263268020P 2022-02-15 2022-02-15
US63/268,024 2022-02-15
US63/268,020 2022-02-15
PCT/EP2023/053752 WO2023156453A1 (en) 2022-02-15 2023-02-15 Phenethylamine derivatives, compositions, and methods of use

Publications (3)

Publication Number Publication Date
JP2025505745A JP2025505745A (ja) 2025-02-28
JP2025505745A5 true JP2025505745A5 (https=) 2026-02-24
JPWO2023156453A5 JPWO2023156453A5 (https=) 2026-02-24

Family

ID=85278142

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547667A Pending JP2025505745A (ja) 2022-02-15 2023-02-15 フェネチルアミン誘導体、組成物、及び使用方法

Country Status (7)

Country Link
US (1) US20250145566A1 (https=)
EP (1) EP4479372A1 (https=)
JP (1) JP2025505745A (https=)
KR (1) KR20240153567A (https=)
AU (1) AU2023222126A1 (https=)
CA (1) CA3244130A1 (https=)
WO (1) WO2023156453A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122741B2 (en) 2020-08-18 2024-10-22 Cybin Irl Limited Therapeutic phenethylamine compositions and methods of use
CA3209813A1 (en) 2021-07-14 2023-01-19 Mydecine Innovations Group Inc. Novel short-acting psychoactive compounds of the mdma class
CA3218730A1 (en) * 2022-02-28 2023-08-31 Denton W. Hoyer Novel prodrug compounds of 3,4-methylenedioxymethamphetamine (mdma) and methods of synthesizing the same
WO2024056678A1 (en) * 2022-09-12 2024-03-21 Mihkal Gmbh Novel nootropic prodrugs of phenethylamine
WO2025228547A1 (en) * 2024-05-01 2025-11-06 Cybin Irl Limited Processes for preparing phenethylamine compounds
US20250353808A1 (en) * 2024-05-17 2025-11-20 2A Biosciences, Inc. 5-methoxymethyl and 5-hydroxymethyl phenethylamines
CN120501709B (zh) * 2025-06-03 2025-12-12 暨南大学 硫酸多黏菌素b干粉、吸入粉雾剂及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
ID28302A (id) 1999-01-14 2001-05-10 Teijin Ltd Alat untuk mengumpankan suatu bubuk dalam jumlah tertentu
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
NZ514442A (en) 1999-03-03 2003-08-29 Optinose As Nasal delivery device
GB0019715D0 (en) 2000-08-10 2000-09-27 Pa Consulting Services Device for delivering physiologically active agent in powdered form
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
JP4795637B2 (ja) 2001-09-28 2011-10-19 カーブ テクノロジー,インコーポレイティド 鼻ネブライザー
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
US7267121B2 (en) 2004-04-20 2007-09-11 Aerogen, Inc. Aerosol delivery apparatus and method for pressure-assisted breathing systems
WO2008016677A2 (en) * 2006-08-02 2008-02-07 Auspex Pharmaceuticals, Inc. Preparation and utility of deuterated amphetamines
CN112430187B (zh) * 2019-08-07 2023-01-17 北京奇点势能科技有限公司 一种α,β-氘代胺类化合物、氘代药物及其制备方法
RU199823U1 (ru) 2020-06-10 2020-09-21 Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий Устройство для лечения бронхолегочных заболеваний

Similar Documents

Publication Publication Date Title
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13150U (https=)
BY13164U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY13149U (https=)
BY13162U (https=)